Synthetic Biologics Inc. has received three patent applications for a microbiome designed to protect the gut.
The U.S. Patent and Trademark Office gave the Notices of Allowances for the patents, which will provide coverage of matter claims. The applications will provide methods for protecting the gut from infection and diarrhea.
Synthetic Biologics will have its proprietary product, SYN-004, further protected by the new patent allowances.
"These new patents will complement our growing SYN-004 patent estate and support our C. difficile prevention program, including two ongoing phase-two clinical trials," Jeffrey Riley, president and CEO of Synthetic Biologics, said. "We're on schedule with respect to patient enrollment in our global Phase 2b proof-of-concept clinical trial intended to evaluate the ability of SYN-004 to prevent CDI and AAD in patients hospitalized with a lower-respiratory tract infection."
The SYN-004 product is designed to help balance microbiomes in the gut. Synthetic has multiple patents for similar products that extend until 2031 to 2035.
"During the first half of 2016, we also anticipate announcing top-line data from the second Phase 2a clinical trial, which is evaluating the ability of SYN-004 to degrade IV ceftriaxone in the presence of a proton pump inhibitor," Riley said.